Clinical Trial Update: A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and tolerability of MK0517 for the prevention of postoperative nausea and vomiting has completed. Results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Nausea and Vomiting

Drugs mentioned

• MK0517

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Post-Operative Nausea and Vomiting | Phase 3 | Status: COMPLETED | Results posted: 2010-06-08